PONTE
VEDRA, Fla., Feb. 1, 2023
/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq:
CVKD) a biopharmaceutical company focused on developing tecarfarin,
a clinical-stage novel cardiorenal therapy with orphan drug and
Fast Track designations, announced today the formation of its
Scientific Advisory Board (SAB) in support of the development of
tecarfarin for the prevention of systemic thromboembolism, more
commonly referred to as blood clots, of cardiac origin in patients
with end-stage renal disease and atrial fibrillation (ESRD +
AFib).
"We have assembled a world-class group of anticoagulant, medical
and scientific experts to provide strategic guidance to Cadrenal,"
commented Quang Pham, Chief
Executive Officer of Cadrenal. "This diverse and talented group
will be incredibly valuable as we look to accomplish our mission of
advancing patient care in cardiorenal diseases."
"Cadrenal is fortunate to have engaged thought leaders in the
key disciplines involved in our tecarfarin program. We look forward
to their guidance as we advance this program to completion," said
Dr. Douglas Losordo, Chief Medical
Officer of Cadrenal.
Members of the Cadrenal SAB include:
Christopher Bull Granger,
MD
- Professor of Medicine in the Division of Cardiology at
Duke University
- Director of Cardiac Care Unit for Duke
University Medical Center
- Member, Duke Clinical Research Institute (DCRI)
- Principal Investigator, ARISTOTLE TRIAL
Elaine Hylek, MD, MPH
- Professor of Medicine at Boston University
School of Medicine
- Section Editor for Thrombosis and Haemostasis and the Director
of the Thrombosis and Anticoagulation Service at Boston Medical
Center.
- Member, Evans Center for Interdisciplinary Biomedical Research,
Boston University
- Associate Director of the Education and Training Division of
the Boston University Clinical
Translational Science Institute
Michael Gibson, MS, MD
- CEO of not-for profit Baim/PERFUSE Research Institutes
- Harvard University Professor
- Cardiologist at Beth Israel Deaconess Medical Center of
Boston
- Founder and Chairman WikiDoc.org
Richard Whitlock, MD
- Cardiac Surgeon and Associate Professor at Population Health
Research Institute, McMaster University
Medical Center
- Investigator, Population Health Research Institute
Sean Pokorney, MD, MBA
- Designated as Principal Investigator
- Cardiologist, electrophysiologist and researcher specializing
in patients with ESRD and AFib.
- Assistant Professor of Medicine at Duke
University and is a member of the Duke Clinical Research
Institute
- Co-Principal Investigator, RENAL-AF
Michael Lincoff, MD
- Vice Chairman, Department of Cardiovascular Medicine, Cleveland
Clinic
- Director of Clinical Research, Lerner Research Institute
Wolfgang C. Winkelmayer, MD,
MPH, ScD
- Chief, Section of Nephrology and Professor of Medicine,
Baylor College of Medicine
- Director, Selzman Institute for Kidney Health at Baylor College of Medicine
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is focused on developing tecarfarin, a
novel cardiorenal therapy with orphan drug and Fast Track
designations for the prevention of systemic thromboembolism (blood
clots) of cardiac origin in patients with end-stage renal disease,
or ESRD, and atrial fibrillation (irregular heartbeat), or AFib.
Tecarfarin is a Vitamin K antagonist oral anticoagulant designed to
target a different pathway than the most commonly prescribed drugs
used in the treatment of thrombosis and AFib. Tecarfarin has been
evaluated in eleven human clinical trials and more than 1,000
individuals. In Phase 1, Phase 2 and Phase 2/3 clinical trials,
tecarfarin has generally been well-tolerated in both healthy adult
subjects and patients with chronic kidney disease. For more
information, please visit: www.cadrenal.com.
Safe Harbor Statement
Any statements contained in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements." These statements include statements
regarding looking to advancing patient care in cardiorenal
diseases and advancing the program to completion. The
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including the ability to advance the program to
completion, the ability to advance patient care in cardiorenal
diseases and the other factors discussed in the "Risk Factors"
section of the initial public offering prospectus filed with the
SEC. Any forward-looking statements contained in this press release
speak only as of the date hereof and, except as required by federal
securities laws, Cadrenal Therapeutics specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700,
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-announces-formation-of-scientific-advisory-board-301735198.html
SOURCE Cadrenal Therapeutics, Inc.